PMID- 33997857
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231219
IS  - 2673-3080 (Electronic)
IS  - 2673-3080 (Linking)
VI  - 3
DP  - 2021 Mar
TI  - Considering intrauterine location in a model of fetal growth restriction after 
      maternal titanium dioxide nanoparticle inhalation.
LID - 643804 [pii]
LID - 10.3389/ftox.2021.643804 [doi]
AB  - Fetal growth restriction (FGR) is a condition with several underlying etiologies 
      including gestational disease (e.g., preeclampsia, gestational diabetes) and 
      xenobiotic exposure (e.g., environmental contaminants, pharmaceuticals, 
      recreational drugs). Rodent models allow study of FGR pathogenesis. However, 
      given the multiparous rodent pregnancy, fetal growth variability within uterine 
      horns may arise. To ascertain whether intrauterine position is a determinant of 
      fetal growth, we redesigned fetal weight analysis to include litter size and 
      maternal weight. Our FGR model is produced by exposing pregnant Sprague Dawley 
      rats to aerosolized titanium dioxide nanoparticles at 9.44 +/- 0.26 mg/m(3) on 
      gestational day (GD) 4, GD 12 or GD 17 or 9.53 +/- 1.01 mg/m(3) between GD 4-GD 19. 
      In this study fetal weight data was reorganized by intrauterine location [i.e., 
      right/left uterine horn and ovarian/middle/vaginal position] and normalized by 
      maternal weight and number of feti per uterine horn. A significant difference in 
      fetal weight in the middle location in controls (0.061g +/- 0.001 vs. 0.055g +/- 
      0.002), GD 4 (0.033g +/- 0.003 vs. 0.049g +/- 0.004), and GD 17 (0.047g +/- 0.002 vs. 
      0.038g +/- 0.002) exposed animals was identified. Additionally, GD 4 exposure 
      produced significantly smaller feti in the right uterine horn at the ovarian end 
      (0.052g +/- 0.003 vs. 0.029g +/- 0.003) and middle of the right uterine horn (0.060g 
      +/- 0.001 vs. 0.033g +/- 0.003). GD 17 exposure produced significantly smaller feti 
      in the left uterine horn middle location (0.055g +/- 0.002 vs. 0.033 +/- 0.002). 
      Placental weights were unaffected, and placental efficiency was reduced in the 
      right uterine horn middle location after GD 17 exposure (5.74g +/- 0.16 vs. 5.09g +/- 
      0.14). These findings identified: 1) differences in fetal weight of controls 
      between the right and left horns in the middle position, and 2) differential 
      effects of single whole-body pulmonary exposure to titanium dioxide nanoparticles 
      on fetal weight by position and window of maternal exposure. In conclusion, these 
      results indicate that consideration for intrauterine position, maternal weight, 
      and number of feti per horn provides a more sensitive assessment of FGR from 
      rodent reproductive and developmental studies.
FAU - D'Errico, J N
AU  - D'Errico JN
AD  - Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, 
      Rutgers University, 160 Frelinghuysen Rd., Piscataway, NJ 08854, USA.
FAU - Fournier, S B
AU  - Fournier SB
AD  - Environmental and Occupational Health Sciences Institute, 170 Frelinghuysen Rd., 
      Piscataway, NJ 08854, USA.
FAU - Stapleton, P A
AU  - Stapleton PA
AD  - Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, 
      Rutgers University, 160 Frelinghuysen Rd., Piscataway, NJ 08854, USA.
AD  - Environmental and Occupational Health Sciences Institute, 170 Frelinghuysen Rd., 
      Piscataway, NJ 08854, USA.
LA  - eng
GR  - P30 ES005022/ES/NIEHS NIH HHS/United States
GR  - R00 ES024783/ES/NIEHS NIH HHS/United States
GR  - R01 ES031285/ES/NIEHS NIH HHS/United States
GR  - T32 ES007148/ES/NIEHS NIH HHS/United States
PT  - Journal Article
DEP - 20210323
PL  - Switzerland
TA  - Front Toxicol
JT  - Frontiers in toxicology
JID - 101777990
CIN - Front Toxicol. 2023 Dec 04;5:1293873. PMID: 38111537
PMC - PMC8121264
MID - NIHMS1695404
OTO - NOTNLM
OT  - fetal growth restriction
OT  - intrauterine position
OT  - titanium dioxide nanoparticles
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/05/18 06:00
MHDA- 2021/05/18 06:01
PMCR- 2021/03/23
CRDT- 2021/05/17 06:27
PHST- 2021/05/17 06:27 [entrez]
PHST- 2021/05/18 06:00 [pubmed]
PHST- 2021/05/18 06:01 [medline]
PHST- 2021/03/23 00:00 [pmc-release]
AID - 643804 [pii]
AID - 10.3389/ftox.2021.643804 [doi]
PST - ppublish
SO  - Front Toxicol. 2021 Mar;3:643804. doi: 10.3389/ftox.2021.643804. Epub 2021 Mar 
      23.